As a Free StocksGuide user, you can view scores for all 7,012 stocks worldwide.
7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:
7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:
Jun '25 |
+/-
%
|
||
Revenue | 45 45 |
4%
4%
|
|
Gross Profit | 25 25 |
4%
4%
|
|
EBITDA | -51 -51 |
20%
20%
|
EBIT (Operating Income) EBIT | -53 -53 |
18%
18%
|
Net Profit | -74 -74 |
35%
35%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.
Head office | United States |
CEO | Robert Gordon |
Employees | 120 |
Founded | 2016 |
Website | celularity.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.